Clinical Trial

Idiopathic Generalized Epilepsy Syndromes

Recruiting
View on ClinicalTrials.gov →
Summary
The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance. According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-24.
Trial Details
NCT Number NCT06388174
Lead Sponsor Shen Chun-Hong
Conditions Epilepsy, Epilepsy, Idiopathic Generalized
Enrollment 200 participants
Start Date 2023-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-27